Puma Biotechnology News

Investors Don't See Light At End Of Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Tunnel And Push Stock Down 33%

The Puma Biotechnology, Inc. (NASDAQ:PBYI) share price has fared very poorly over the last month, falling by a substantial 33%. Instead of being rewarded, shareholders who have already held through

Simply Wall StJun 15 20:46

We Think Shareholders Are Less Likely To Approve A Pay Rise For Puma Biotechnology, Inc.'s (NASDAQ:PBYI) CEO For Now

Key Insights Puma Biotechnology to hold its Annual General Meeting on 18th of June Total pay for CEO Alan Auerbach includes US$877.9k salary Total compensation is similar to the industry average

Simply Wall StJun 12 18:54

PUMA Continues Its Biggest Marketing Push With EURO and COPA Spin-Offs

HERZOGENAURACH, Germany--(BUSINESS WIRE)--Global sports company PUMA has launched the second chapter of its first worldwide brand campaign in 10 years "FOREVER. FASTER. - See The Game Like We Do". New

BusinesswireJun 12 16:00

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on June 6, 2024, the Compensation Committee of Puma's Board of Directors approved the grant of an inducement restricted stock unit

BusinesswireJun 8 05:37

Beyond The Numbers: 4 Analysts Discuss Puma Biotechnology Stock

Ratings for Puma Biotechnology (NASDAQ:PBYI) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.The table below summarizes their recent ratings,

BenzingaJun 4 23:01

Puma Biotechnology Announces Presentation of Findings From a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer

Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced the presentation of alisertib for the treatment of patients with advanced osimertinib-resistant epidermal growth factor receptor-mutated

BusinesswireJun 4 02:33

HC Wainwright & Co. Reiterates Buy on Puma Biotechnology, Maintains $7 Price Target

HC Wainwright & Co. analyst Edward White reiterates Puma Biotechnology (NASDAQ:PBYI) with a Buy and maintains $7 price target.

BenzingaJun 3 19:42

Buy Rating Reaffirmed for Puma Biotechnology Amid Promising Alisertib Developments and Orphan Drug Designation

TipRanksJun 3 18:15

Puma Biotechnology Announces Presentation of Phase II Study Results of Alisertib for Endocrine Resistant Metastatic Breast Cancer (Tbcrc 041)

Puma Biotechnology Announces Presentation of Phase II Study Results of Alisertib for Endocrine Resistant Metastatic Breast Cancer (Tbcrc 041)

Zhitong FinanceJun 2 22:05

Express News | Puma Biotechnology Announces Presentation of Findings From a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (Tbcrc 041)

BreakingsJun 2 22:03

Puma Biotechnology to Join Russell 3000 Index

Business WireMay 28 21:00

With 49% Ownership, Puma Biotechnology, Inc. (NASDAQ:PBYI) Has Piqued the Interest of Institutional Investors

Yahoo FinanceMay 26 20:36

Puma Biotechnology (PBYI) Falls 38% in 3 Months: Here's Why

Yahoo FinanceMay 24 23:57

Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting

Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced the release of abstracts on alisertib to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The ASCO

BusinesswireMay 24 05:15

Implied Volatility Surging for Puma Biotechnology (PBYI) Stock Options

Yahoo FinanceMay 20 21:59

TD Cowen Sticks to Its Hold Rating for Puma Biotechnology (PBYI)

TipRanksMay 20 19:17

Analysts Offer Insights on Healthcare Companies: Oscar Health (OSCR), Puma Biotechnology (PBYI) and Patterson Companies (PDCO)

TipRanksMay 20 18:21

Puma Biotechnology Says Jury Verdict Was Entered In Favor Of Wyeth, And Against AstraZeneca; Jury Found '314 & '162 Patents To Be Infringed By AstraZeneca And Not Invalid, Awarded Plaintiffs $107.5M In Damages

Puma Biotechnology Says Jury Verdict Was Entered In Favor Of Wyeth, And Against AstraZeneca; Jury Found '314 & '162 Patents To Be Infringed By AstraZeneca And Not Invalid, Awarded Plaintiffs $107.5M I

BenzingaMay 18 04:49

Puma Biotech Surges Amid Wyeth Victory in Tagrisso Patent Case

Seeking AlphaMay 18 03:10

Puma Posts Lower Earnings After Sales Suffer Currency Headwind

By Pierre Bertrand Puma reported a decline in first-quarter earnings after sales were hit by unfavorable currency effects. The German sporting-goods company said it made 87.3 million euros ($93.9 mi

WSJMay 8 14:31